Incidence of acute
hepatitis C virus (HCV) infection increased significantly among young,
non-urban people who inject drugs in the United States between 2006 and 2012,
investigators report in the online edition of Clinical Infectious Diseases.
“The incidence of
reported acute hepatitis C among young persons has significantly increased
during 2006-12, with annual increases over two times greater in non-urban
compared to urban jurisdictions,” write the authors. “Reported incidence was
greater in 2012 than 2006 in at least 30 states, most notably in non-urban
jurisdictions east of the Mississippi River in or nearby Appalachian counties.”
The authors call for a comprehensive plan to tackle this “worrisome” emergent
HCV now surpasses
HIV as a cause of death in the US. Incidence of acute HCV infection was falling
before 2003 but has been increasing since 2006, especially among younger people
(under 30 years of age) who inject drugs. Data from individual states suggests
that there are emergent HCV epidemics among younger non-urban people who inject drugs, with the infections linked to the injecting of prescription opioids.
To see if this was
representative of a wider national trend, investigators analysed data collected
by the Centers for Disease Control and Prevention (CDC) on the epidemiology of acute HCV infections between 2006 and 2012.
Detailed data from 2011-12 were examined to see if there were any specific risk
factors associated with new HCV infections among younger people who inject drugs.
A total of 7169
acute HCV infections were reported between 2006 and 2012; information on age
was available for 7077 cases, and 44% of patients were aged 30 years or younger. In
2006, 36% of infections involved younger people, increasing to 49% in 2012.
Annual incidence among younger people was significantly higher in 2012
compared to 2006 (p = 0.002).
Of the 34 states
and territories reporting to the CDC, 30 (88%) reported a higher incidence of
acute HCV in 2012 compared to 2006. Half of these states had an increases of
over 200%. The five states with the most cases in 2012 were Kentucky,
Tennessee, Georgia, Indiana and Florida. The authors note all are east of the
Mississippi River, in or near Appalachian jurisdictions.
Of the 102 counties
reporting an incidence of acute HCV above 10 cases per 100,000 in 2012, 89%
were east of the Mississippi River, most commonly in the Appalachians.
Of the young
people with acute HCV, 69% lived in urban settings and 31% in non-urban
counties. The incidence of acute HCV increased by 13% overall with a 170%
increase between 2006 and 2012 in non-urban jurisdictions (p = 0.003).
Between 2006 and
2012, the highest annual incidence was in 2012 for both non-urban (1.22 per
100,000) and urban (0.55 per 100,000) jurisdictions.
for 2011-12 were available for 1202 people. Over half (52%) were female, 56%
lived outside large metropolitan areas, 85% were white and 44% were aged in
their early 20s.
three quarters were insured and had undergone treatment for alcohol or drug
abuse. A third reported being in jail in the year before their infection with
HCV. Over three quarters (77%) reported ever injecting drugs. Of these, 57%
said they had shared needles or syringes and 82% reported the sharing of other
the younger patients revealed that 84% had ever used drugs (alcohol included)
with 76% reporting use of prescription opioids. Average age of first use of an
injectable drug was a little under 20 years. Over half (54%) said they used
both prescription opioids and heroin, with use of prescription opioids
initiated an average of two years before injecting of heroin.
approach is needed to address the increases in HCV infection among young
persons,” comment the investigators. “The early abuse of prescription opioids
presents an opportunity to mitigate high-risk behaviors.” The authors also call
for surveillance of the HCV epidemic to be strengthened and for HCV testing and
preventing services to be offered at drug and alcohol services and in prisons.
They also suggest the expanded use of newer anti-HCV drugs offers the promise
of “treatment as prevention” with models suggesting “even modest increases in
HCV treatment among people who inject drugs can reduce prevalence.”
conclude, “reducing HCV incidence among young persons is achievable, but
requires a comprehensive, integrative strategy in response to this emergent